Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Sponsor: Mike Quigley (Democratic-IL)April 6, 2026

AI-generated ?

Report an error

Introduced

In Committee

Passed One Chamber

Passed Both Chambers

Signed into Law

Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.

Extends federal support for ALS research and requires FDA to plan for rare brain diseases.

This bill would continue federal support for research into Amyotrophic Lateral Sclerosis (ALS). It would extend the current research program and grants through the government's budget year 2031. It would also require the Food and Drug Administration (FDA) to create a public plan for how it will help develop therapies for rare brain conditions.

What Would Change

Today, federal support for ALS research and related grants is set to end in the government's budget year 2026, and the Food and Drug Administration (FDA) is not required to publish a specific action plan for rare brain diseases. If this bill becomes law, federal support for ALS research and grants would continue through the government's budget year 2031. The FDA would also be required to publish a 5-year action plan for rare brain diseases within 18 months and a report on its progress within 5 years.

Key Provisions

Extends federal funding permission for ALS research through the government's budget year 2031.
Requires the Food and Drug Administration (FDA) to publish a 5-year action plan for rare brain diseases within 18 months of the bill becoming law.
Requires the FDA to publish a report on its actions under that plan within 5 years of the bill becoming law.
Requires the Secretary of Health and Human Services to review patient enrollment, safety, and efficacy data when renewing ALS research grants.
Requires groups receiving ALS research grants to quickly report any new, serious, or unexpected safety issues from late-stage clinical trials.

View on Congress.gov

HR 8205 · 119th Congress · April 6, 2026 · AI Summary by gemini-2.5-flash · 10/10

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

What Would Change

Key Provisions

Lobbying Activity